Assuntos
Neoplasias Esofágicas , Carcinoma de Células Escamosas do Esôfago , Anemia de Fanconi , Humanos , Carcinoma de Células Escamosas do Esôfago/tratamento farmacológico , Carcinoma de Células Escamosas do Esôfago/genética , Anemia de Fanconi/complicações , Anemia de Fanconi/tratamento farmacológico , Anemia de Fanconi/genética , Neoplasias Esofágicas/tratamento farmacológico , Neoplasias Esofágicas/genética , Células Germinativas , Mutação , Proteína do Grupo de Complementação A da Anemia de Fanconi , Proteína BRCA2/genéticaRESUMO
Endocrine therapy forms the backbone of systemic therapy for the majority of persons with early and late-stage breast cancer. However, the side effects can negatively affect quality of life, and impact treatment adherence and overall oncological outcomes. Adverse effects on cognition are common, underreported and challenging to manage. We aim to describe the nature, incidence, risk factors and underlying mechanisms of endocrine therapy-induced cognitive dysfunction. We conducted a comprehensive literature review of the studies reporting on cognitive dysfunction associated with endocrine therapies for breast cancer. We also summarise prevention and treatment strategies, and ongoing research. Given that patients are taking endocrine therapies for longer durations than ever before, it is essential that these side effects are managed pro-actively within a multi-disciplinary team in order to promote adherence to endocrine therapy and improve patients' quality of life.